The evolution of cellular deficiency in GATA2 mutation
2013; Elsevier BV; Volume: 123; Issue: 6 Linguagem: Inglês
10.1182/blood-2013-07-517151
ISSN1528-0020
AutoresRachel Dickinson, Paul Milne, Laura Jardine, Sasan Zandi, Sabina Świerczek, Naomi McGovern, Sharon Cookson, Zaveyna Ferozepurwalla, Alexander Langridge, Sarah Pagan, Andrew R. Gennery, Tarja Heiskanen‐Kosma, Sari Hämäläinen, Mikko Seppänen, MATTHEW HELBERT, Eleni Tholouli, Eleonora Gambineri, Sigrún Reykdal, Magnús Gottfreðsson, James Thaventhiran, Emma Morris, Gideon M. Hirschfield, Alex Richter, Stephen Jolles, Chris M. Bacon, Sophie Hambleton, Muzlifah Haniffa, Yenan T. Bryceson, Carl E. Allen, Josef T. Prchal, John E. Dick, Venetia Bigley, Matthew Collin,
Tópico(s)Immunodeficiency and Autoimmune Disorders
ResumoKey Points Diverse patient groups with GATA2 mutation develop mononuclear cytopenia and elevated Flt3 ligand. Progressive cytopenias, rising Flt3 ligand, and terminal differentiation of lymphoid cells accompany clinical progression.
Referência(s)